Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease)

British Journal of Cancer

Volumn 95, Issue 4, 2006, Pages 470-474

  Phernambucq, E C J ^a   Biesma, B ^b   Smit, E F ^a,c   Paul, M A ^a   Tol, A Vd ^c   Schramel, F M ^d   Bolhuis, R J ^b   Postmus, P E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JEROEN BOSCH HOSPITAL   (Netherlands)

^c MARTINI HOSPITAL   (Netherlands)

^d ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Induction chemotherapy; N2 disease; Non small cell lung cancer

Indexed keywords

CISPLATIN; EPIRUBICIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MEDIASTINUM LYMPH NODE; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EPIRUBICIN; ERYTHROPOIETIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEDIASTINUM; MIDDLE AGED; PNEUMONECTOMY; SURVIVAL ANALYSIS;

EID: 33747175916     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603289     Document Type: Article

References (28)

1. Abels R (1993) Erythropoietin for anaemia in cancer patients. Eur J Cancer 29A(Suppl 2): S2-S8
2. Akhurst T, Downey RJ, Ginsberg MS, Gonen M, Bains M, Korst R, Ginsberg RJ, Rusch VW, Larson SM (2002) An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg 73: 259-264
3. Albain KS, Schwann RS, Rusch VR, Turrisi AT, Shepherd FA, Smith CJ, Gandara DR, Johnson DH, Green MR, Miller RC (2005) Phase III study of concurrent chemotherapy and full course radiotherapy (CT/RT) versus CT/RT induction followed by surgical resection for stage IIIa(pN2) non-small cell lung cancer (NSCLC); first outcome analysis of North American Intergroup trial 0139 (RTOG 93-09). J Clin Oncol 23: 624s
4. Annema JT, Versteegh MI, Veselic M, Welker L, Mauad T, Sont JK, Willems LN, Rabe KF (2005) Endoscopic ultrasound added to mediastinoscopy for preoperative staging of patients with lung cancer. JAMA 294: 931-936
5. Betticher DC, Hsu Schmitz SF, Totsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris HB (2003) Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 21: 1752-1759
6. Bueno R, Richards WG, Swanson SJ, Jaklitsch MT, Lukanich JM, Mentzer SJ, Sugarbaker DJ (2000) Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 70: 1826-1831
7. Burkes RL, Shepherd FA, Blackstein ME, Goldberg ME, Waters PF, Patterson GA, Todd T, Pearson FG, Jones D, Farooq S, McGlaughlin J, Ginsberg RJ (2005) Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial. Lung Cancer 47: 103-109
8. Cappuzzo F, De Marinis F, Nelli F, Calandri C, Maestri A, Benedetti G, Migliorino MR, Cortesi E, Rastelli F, Martelli O, Andruccetti M, Bartolini S, Crino L (2003) Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer. Lung Cancer 42: 355-361
9. Cascinu S, Del Ferro E, Fedeli A, Ligi M, Alessandroni P, Catalano G (1995) Recombinant human erythropoietin treatment in elderly cancer patients with cisplatin-associated anemia. Oncology 52: 422-426
10. De Leyn P, Vansteenkiste J, Deneffe G, Van Raemdonck D, Coosemans W, Lerut T (1999) Result of induction chemotherapy followed by surgery in patients with stage IIIA N2 NSCLC: importance of pre-treatment mediastinoscopy. Eur J Cardiothorac Surg 15: 608-614
11. Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16: 3412-3425
12. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15: 1218-1234
13. Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, Van Tinteren H, Postmus PE, Golding RP, Biesma B, Schramel FJHM, Van Zandwijk N, Lammertsma AA, Hoekstra OS (2005) Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 23: 8362-8370
14. Huisman C, Biesma B, Postmus PE, Giaccone G, Schramel FM, Smit EF (2001) Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy. Br J Cancer 85: 1456-1461
15. Kaplan E, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
16. Kim JJ, Tannock IF (2005) Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5: 516-525
17. Lee KS, Shim YM, Han J, Kim J, Ahn YC, Park K, Jung KJ (2000) Primary tumors and mediastinal lymph nodes after neoadjuvant concurrent chemoradiotherapy of lung cancer: serial CT findings with pathologic correlation. J Comput Assist Tomogr 24: 35-40
18. Margaritora S, Cesario A, Galetta D, D'Andrilli A, Macis G, Mantini G, Trodella L, Granone P (2001) Ten year experience with induction therapy in locally advanced non-small cell lung cancer (NSCLC): is clinical re-staging predictive of pathological staging? Eur J Cardiothorac Surg 19: 894-898
19. Port JL, Kent MS, Korst RJ, Keresztes R, Levin MA, Altorki NK (2004) Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg 77: 254-259
20. Rosell R, Gomez-Codina J, Camps C, Javier SJ, Maestre J, Padilla J, Canto A, Abad A, Roig J (1999) Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 26: 7-14
21. Roth JA, Atkinson EN, Fossella F, Komaki R, Bernadette RM, Putnam Jr JB, Lee JS, Dhingra H, De Caro L, Chasen M, Hong WK (1998) Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 21: 1-6
22. Savonije JH, van Groeningen CJ, van Bochove A, Honkoop AH, van Felius CL, Wormhoudt LW, Giaccone G (2005) Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial. Eur J Cancer 41: 1560-1569
23. Sawabata N, Keller SM, Matsumura A, Kawashima O, Hirono T, Osaka Y, Maeda H, Fukai S, Kawahara M (2003) The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer. Lung Cancer 42: 69-77
24. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
26. Van Meerbeeck JP, Kramer G, Van Schil PEY, Legrand C, O'Brien M, Manegold C, Giaccone G, Van Zandwijk N, Splinter TAW (2003) Induction chemotherapy (CT) in stage IIIA-N2 non-small cell lung cancer (NSCLC): an analysis of different regimens used in EORTC 08941. Lung cancer 41: S79-S80
27. Van Meerbeeck JP, Kramer G, Van Schil PE, Legrand C, Smit EF, Schramel FM, Biesma B, Tjan-Heijnen VC, Van Zandwijk N, Giaccone G (2005) A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941). J Clin Oncol 23: 1095s
28. Van Zandwijk N, Smit EF, Kramer GW, Schramel F, Gans S, Festen J, Termeer A, Schlosser NJ, Debruyne C, Curran D, Giaccone G (2000) Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 18: 2658-2664